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Introduction
Chlamydia trachomatis (Ct) infection is a serious public-health problem. It is a cause of chronic conjuctivitis and is worldwide the most common sexually transmitted bacterial infection (STI) with more than 90 million new cases occurring annually [1] . Infection can result in scarring and fibrosis of ocular and genital tissues. The result is trachoma and pelvic inflammatory disease, respectively [2, 3] . Chlamydial urogenital tract infections are treatable with antibiotics, but due to a high frequency of asymptomatic infections, control and elimination of the disease is difficult. There are indications that the risk of re-infection after antibiotic treatment of a previous infection is high -13-26% [4] . Moreover, Ct enhances transmission of the human immunodeficiency virus (HIV) and may serve as a cofactor in human papilloma virus (HPV) infection [5, 6] . This means that the control of Ct STIs may be possible only through the development of a safe and efficient vaccine. Such progress is slow but of high priority.
Major efforts in anti-chlamydial vaccine development are focused on subunit vaccines using the major outer membrane protein (MOMP) of C. trachomatis as the target antigen. MOMP is the most abundant and one of the most studied proteins for use as a Ct vaccine candidate [1, 7] . It was shown that MOMP is able to induce both T-cell responses and neutralizing antibody production against chlamydial infection [8, 9] . However, despite useful animal models, it has been difficult to achieve complete protection against Ct infection using anti-chlamydial subunit vaccines in animal experiments [1, 9, 10] . One probable reason for this is the use of an inefficient delivery system. Vaccine delivery is important in the case of STIs since mucosal immunity has to be achieved. Mucosal immunity can for instance be initiated through either the oral or the intranasal delivery route [11] [12] [13] [14] . Plant-based edible vaccines or purified recombinant antigen protein for intra-nasal delivery are good candidates for mucosal 4 immunization. Especially plant-made proteins are generally safe and cheap, which opens up for a possibility to provide a high frequency of booster immunizations. Also, a transgenic plant is capable of producing several different antigens as a result of crossing parental lines producing different proteins.
The potential of the gut-associated lymphoid tissues (GALT) for induction of protective immune responses has hitherto only marginally been explored. Edible plant vaccines against enterotoxic Escherichia coli (ETEC; Refs. 14 & 15) , cholera toxin [17, 18] , and norovirus [19, 20] have already passed pre-clinical trials and preliminary human clinical trials show very promising results -transgenic plants can stimulate a two-way immune response, both systemically and mucosally. Improvement of administration protocols and the use of adjuvants during oral vaccination could then be important ways of further increasing efficacy of edible vaccines.
The aim of this study was to develop a recombinant mucosal immunogen for Ct by combining two antigenic regions of the MOMP protein and decreasing the protein's hydrophobicity. The chimeric protein was overexpressed in E. coli and purified by immobilized metal affinity chromatography (IMAC). The genetic construct for this chimera was also introduced into the model plant Arabidopsis thaliana and into carrot (Daucus carota) and substantial production of the antigen was shown. The transgenic plants are planned for use as a production platform for the antigen or as edible vaccine vectors for laboratory animal experiments.
Material and methods

The MOMP constructions for overexpression in Escherichia coli
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Total genomic DNA was isolated from a bacterial suspension (Örebro University Hospital, Örebro, Sweden), emanating from a Chlamydia trachomatis serovar E infected patient, using QIAamp ® DNA Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's protocol.
PCR amplification of the full-length MOMP for overexpression in Escherichia coli was performed using Ex Taq DNA polymerase (Takara Bio Inc, Shiga, Japan) and primers FL MOMP, forward 2 and FL MOMP, reverse 2 ( Table 1 ). The PCR consisted of 35 cycles at 98ºC (10 s), 55ºC (30 s), and 72ºC (2 min) followed by extension at 72ºC (15 min).
The PCR product was purified with QIAquick PCR Purification Kit (Qiagen, Hilden, Germany) and cloned into the pET101 vector and verified by sequencing.
For the chimeric MOMP construct, the initial amplification of two DNA fragments (VS2 and VS4) of Chlamydia trachomatis MOMP, both containing B and T cell epitopes, was performed from the prepared genomic DNA using primers VS2,forward1, VS2,reverse1 and VS4,forward1, VS4,reverse1 (Table1). The PCR reactions utilized Ex Taq DNA polymerase (Takara Bio Inc, Shiga, Japan) and consisted of 35 cycles at 98ºC (10 s), 55ºC (30 s), and 72ºC (1 min) followed by extension at 72ºC (15 min). The PCR products were purified with QIAquick PCR Purification Kit (Qiagen, Hilden, Germany) and subjected to a second PCR performed under the same conditions as the first PCR but with primers VS2,forward2&3 and VS2,reverse2 for the VS2 extended fragment and VS4,forward2 and VS4,reverse2&3 for the VS4 extended fragment (Table1). The PCR primers for amplifying the VS2 and VS4 fragments also contained sequences for an amino acid linker [(Gly 4 Ser) 2 Gly 4 ] between the two domains. The purified extended VS2 and VS4 fragments were spliced by overlap extension [21] using the following conditions: 10 cycles at 95ºC (1 min), 55ºC (1 min), 72ºC (2 min), followed by extension at 72ºC for 15 min. The spliced 6 product was used for a third PCR utilizing Pfx Taq-polymerase (Invitrogen, Carlsbad, CA) and 25 cycles at 94ºC (15 s), 55ºC (30 s), 72ºC (2 min) followed by a single extension step at 72ºC (30 min). The last PCR amplification was performed using primers VS2,forward2&3
and VS4,reverse2&3 (Table. 1 ). The PCR product obtained was purified as described above.
Cloning and expression of the full-length MOMP and the MOMP chimera in
Escherichia coli
The purified full-length MOMP DNA and chimeric MOMP construct were cloned into the pET101/D-TOPO ® vector using the Champion pET Directional TOPO ® Expression Kit (Invitrogen, Groningen, The Netherlands) according to the manufacturer's protocol ( was inoculated with 10 ml of a fresh overnight culture derived from a single colony of transformed E. coli and grown at 37ºC to an optical density (OD) of 0.7 at 600 nm. Isopropyl ß-D-thiogalactoside (IPTG; Invitrogen) was added to a final concentration of 1.5 mM, and the culture was further incubated for 4 hours. Bacteria were harvested by centrifugation (5000 x g, 15 min) and subjected to protein purification (see below).
Protein purification
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The frozen bacterial pellet was first subjected to disintergration using an X-PRESS (AB BIOX, Göteborg, Sweden) with subsequent resuspension in 50 mM sodium phosphate buffer, pH 8.0, containing 300 mM NaCl and 1 mM phenylmethylsulfonyl fluoride (PMSF; SigmaAldrich). After sonication on ice (35 W, 6 x 30 s) and ultracentrifugation (45000 x g, 45 min), two fractions were obtained: one soluble fraction and one insoluble fraction.
The soluble fraction was subjected to purification under native conditions using HIS-Select Nickel Affinity Gel (Sigma-Aldrich) according to the manufacturer's protocol. As equilibration and wash buffer, we used 50 mM sodium phosphate (pH 8.0) with 0.3 M NaCl.
Elution was performed with the same buffer supplemented with a gradient of imidazole, the concentration of which ranged from 50 to 250 mM in 50 mM steps.
The pellet from ultracentrifugation containing the insoluble fraction was resuspended in 0.1 M sodium phosphate (pH 8.0), 8M urea and sonicated as described above. The collected fractions of the eluted protein were analyzed and the ones containing the protein of highest purity were pooled (separately for the native protein and for the denatured protein). The pooled fractions were concentrated by using an Amicon Ultra centrifugal filter device with a molecular weight cut off of 10 KDa (Millipore, Billerica, MA). genomic DNA isolated from a bacterial Chlamydia trachomatis serovar E suspension as the template. The PCR was performed using Pfx Taq-polymerase (Invitrogen) and consisted of 35 cycles at 94ºC for 30 s, 55ºC for 60 s, 72ºC for 3 min followed by a single extension step at 72ºC for 30 min. The purified PCR product was subjected to subcloning into a plant expression vector (see below).
Production of anti-MOMP chimera antibodies in rabbits
The chimeric MOMP was re-amplified from the previously obtained construct using primers VS2,forward2&3 and VS4,reverse,STOP (which introduced a stop codon into the product, Table 1 ) and Pfx Taq-polymerase (Invitrogen) to produce a blunt-end PCR product. PCR was carried out using the following conditions: 35 cycles at 94ºC for 30 s, 55ºC
for 60 s, 72ºC for 2 min followed by a single extension step at 72ºC for 30 min. The PCR product was purified as previously described and used for subcloning into a plant expression vector.
As plant expression vector we used pGreen0229 (Ref. GeneticAnalyser, Applied Biosystems).
Transformation of Arabidopsis
The pGreen0229/chimeric MOMP and pGreen0229/MOMP constructs ( The carrot cells were packed by centrifugation (at 100 g for 1 min). 4-5 ml packed cells were diluted in liquid MS medium to 20 ml and 600 µl of A. tumefaciens carrying the vector pGreen0229/chimeric MOMP in LB medium (optical density 1.5 at 600 nm) was added. The cells and bacteria were co-cultivated for 3 days in darkness at 25 ºC using a shaker (90 rpm).
Transformation of carrot
Seeds of
For selection of transgenic carrot cells, they were repeatedly washed three times by centrifugation in liquid MS medium to remove bacteria and were subsequently imbedded and further cultivated in growth regulator-free medium supplemented with BASTA (0, 1, 5, or 10 µg/ml) and cephotaxime (500 µg/ml) in dim light (1 µmol 
Immunoblotting
To prepare protein samples, Arabidopsis tissue was ground in an extraction buffer containing 
Genomic DNA extraction and Southern blot analysis
Analysis of genomic plant DNA for the number of transgenic inserts was performed only for Arabidopsis plants transformed with the chimeric MOMP construct. Plant genomic DNA was isolated using the JETFLEX Genomic DNA Purification Kit (GENOMED GmbH, Löhne, Germany), and 15 µg DNA was cleaved with either DraI, NdeI or NotI (Sigma-Aldrich).
These enzymes do not cleave the chimeric MOMP sequence. The cleaved DNA was separated by agarose (1%) gel electrophoresis and transferred to Hybond-N membrane (GE Healthcare, Uppsala, Sweden). The membranes were probed with chimeric MOMP DNA labelled with 32 P-dCTP using the random primers DNA labelling system (Invitrogen). The number of bands observed on the X-ray film corresponded to the number of T-DNA insertions in the plant genome.
Northern blot analysis
RNA isolation was performed according to Strid, Chow & Andersson [24] . Samples containing 15 µg of total RNA were electrophoretically separated on a 1.2% agarose gel and transferred to a Hybond-N membrane (GE Healtcare). The probe (full-length MOMP DNA)
was labeled with 32 P-dCTP using the random primers DNA labelling system (Invitrogen).
Blotting and hybridization was performed according to Kalbina and Strid [25] .
Immunofluorescence analysis of antibody reactivity
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To verify the reactivity of our anti-MOMP chimera antibodies produced in rabbits towards the trachomatis MOMP could not be appropriately expressed in A. thaliana. Instead, we decided to design a MOMP-derived protein that was more likely to be expressed in plants and in E.
coli.
The choice of constructs for production of Chlamydia trachomatis chimeric MOMP in bacteria and in plants
Since production of full-length MOMP was not straight-forward, neither in E. coli, nor in plants, a fact that is most likely due to its high content of hydrophobic amino acids, primarily reflected by the presence of 16 transmembrane helices, we wanted to produce a smaller and more hydrophilic protein based on MOMP but which still would retain high antigenicity.
Therefore, we used the putative secondary structure described by Findlay et al [26] for this design and selected large parts of the VS2 and VS4 domains of the MOMP structure (Fig. 3a) .
These domains contain clusters of previously described T and B cell epitopes important for a protective immune response against Ct [27] [28] [29] [30] [31] . This includes also minor stretches of the transmembrane part of the protein, in the vicinity of the loops, since these hydrophobic stretches also contain immunogenic epitopes. In addition, the choice of domains was such that the difference between the primary structure based on Ct serovar E only differed marginally (6 amino acid residues out of 99) from that of serovar D (Fig. 3b) , making it highly likely that the chimera would induce an immune response to both serovars if used as a candidate vaccine antigen. Finally, the choice of an amino acid linker (Fig. 3b) between the two domains and the retained hydrophobic amino acid residues was such that we could envisage two different tertiary structures of the MOMP chimera, one flexible structure (Fig. 3b ) and a more rigid structure (Fig. 3c) , respectively, again maximizing the chimera's function as a vaccine antigen.
Chimeric MOMP construct and its expression in E. coli
The reverse and forward primers used in PCR to amplify the VS2 and VS4 variable regions of MOMP for assembling the chimera were designed from the nucleotide sequence data. The sequence encoding a common flexible linker, [(Gly 4 Ser) 2 Gly 4 ], was introduced into the 5'-end of the VS4,forward2 and VS2,reverse2 primers. The amplified VS2 and VS4 fragments were then assembled as follows: 5'-VS2 -linker -VS4-3' (Fig. 3b) . The genetic construct produced showed the expected size of 351 bp (Fig. 4a) . The product was verified by sequencing and cloned into the pET101 vector (containing sequences encoding C-terminal V5-and His-tags; Fig. 3b ). The expressed protein was detected using both anti-His antibodies (data not shown) and anti-full length MOMP antibodies (Acris Antibodies; Fig. 4b ).
Typically, in a 6000 ml E. coli culture, 70-80 µg per ml of MOMP chimera was obtained with approximately 5% in soluble form, yielding a total of some 20 mg of soluble MOMP chimera protein.
For purification of the MOMP chimera using IMAC technology, we expressed the protein in 2000 ml bacterial cultures. The soluble chimeric protein was purified under both native and denaturing conditions. The elution fractions of chimeric MOMP protein, were purified under native conditions, analyzed by SDS-PAGE and stained with Coomassie Brilliant Blue (not shown). Pure fractions were pooled and were later used in immunization experiments for production of anti-chimeric MOMP polyclonal serum and thereby for verification of immunogenic features of the designed MOMP chimera. Freshly prepared
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MOMP chimera ran as a monomer on SDS-PAGE (Figs. 4 &5 ) whereas the corresponding protein that had been stored in the refrigerator for several months and used as positive controls ran as a dimer (Fig. 8a) . Proteins that had been stored for a few months displayed both bands on SDS-PAGE gels (Fig 8b) .
Production of anti-MOMP chimera antibodies in rabbit and immunofluorescence analysis
The antibodies produced against the native chimeric MOMP were tested against the purified recombinant MOMP chimera. As shown in Fig. 5 , the anti-serum recognized a band of the correct size. At the same time, the pre-serum did not recognize any bands. Affinity chromatography-purified anti-serum did not show a stronger signal to the goal protein (not shown) than the antiserum with lower antibody concentration.
Since the final aim of our project is to obtain an antigen suitable for vaccination, it is important to show that the antibodies raised using the MOMP chimera do recognize the native full-length Ct MOMP protein. Toward this end, immunofluorescence using our anti-MOMP chimera antibodies, produced in rabbits (post-serum), were used to study reactivity towards Ct elementary bodies. High reactivity was obtained as demonstrated by the clearly defined fluorescent dots in Fig. 6a . The rabbit pre-serum did not show specific reactivity towards these Ct elementary bodies (Fig. 6b) . Furthermore, the conjugate itself did not contribute to unspecific binding (fluorescence). This was demonstrated in negative controls without incubation with rabbit serum (Fig. 6c) . thaliana wild type (WT) plants.
MOMP chimera production in
MOMP chimera production in carrot
MOMP chimera production using Daucus carota was also analysed by immunoblotting with monoclonal antibodies to Ct MOMP (Acris Antibodies). Fig. 8a shows the results of a semiquantification of the amounts of MOMP chimeric protein produced using cultivar Karotan (line Kar +; denoted Kar in Fig. 8a ) and cultivar Napoli (line 313/3; denoted 313 in the same coli-produced chimeric MOMP that had been stored in the refrigerator for several months, the protein expressed in carrots always ran as a dimer on SDS-PAGE (Fig. 8) .
The antiserum raised against the E. coli-produced native chimeric MOMP was also tested with plants expressing the transgene. The antiserum recognized the dimeric form of the protein in transgenic carrot (Fig. 8b) but not in the wild-type, whereas the monomer was found in transgenic Arabidopsis lines (not shown). The antibodies are obviously specifically labelling the plant-produced chimeric MOMP.
Discussion
The objective of this study was to create an antigen candidate that could be used for immunization against infection by Chlamydia trachomatis serovars E and D, primarily in laboratory animals, and to express antigen in planta (Arabidopsis thaliana and carrot) as a putative oral vaccine. Finally, we wanted to produce antibodies against the MOMP protein in rabbits to show the protein's potential antigenicity and to be able to use these antibodies as an analytical tool for future studies.
During the course of this study we did not succeed in expressing the full-length MOMP protein in Arabidopsis thaliana plants. Even though we had evidence for the presence of both the transgene (positive PCR) and its transcripts (positive northern blotting results) in planta, we were unable to detect the MOMP protein in plants. This is most likely due to its strong hydrophobicity. The MOMP protein topology was modelled as a 16-stranded membrane-bound β-barrel [26] . In the full-length protein, 128 out of 371 amino acids belonged to the transmembrane part of the protein (34.5%). Expression of MOMP in heterologous systems such as E. coli has also previously proved to be highly problematic, since the protein tends to misfold and aggregate [32] , a result that was also repeated in our study.
Due to these severe problems with expression of the full-length MOMP, another approach was taken. The new design was based on an analysis of the entire MOMP sequence and thereby merging of certain highly antigenic regions of MOMP to form a chimeric polypeptide, and at the same time minimization of the number of hydophobic amino acids belonging to transmebrane helices. We have combined in our construct both epitopes important for a cell-mediated immune response (T helper cells and cytotoxic T-lymphocytes)
as well as neutralizing antibodies, which are necessary for the creation of a protective immune response against Ct. T-cell stimulating epitopes for human leukocyte antigen (HLA) class I and HLA class II recognition, that are mainly situated in the constant domains (CDs) of the MOMP [27] , are included in the chimera. The chimera also contains epitopes for antibody recognition that are present in the variable domain regions (VDs) of MOMP ( Fig. 3a; Ref.
28). However, some small hydrophobic stretches containing immunogenic epitopes were kept 20 in the new chimera (see Fig. 3 ). Also, we wanted to express a chimeric protein, based on the serovar E amino acid sequence, that was as similar as possible to the serovar D sequence, with the aim to produce an antigen candidate protein that would be able to evoke an immune response against both serovars. In this way, we could use the serovar D-based animal model of our research partners to study the potential of our construct to cause cross-serovar protection (work in progress).
Again, the chimera contains hydrophobic parts of three transmembrane helices partly since important peptides for T-cell activation are located there and since it is necessary to obtain a stimulatory T-cell response in order to obtain a functional vaccine against Ct [29] , but also partly since clustering of these hydrophobic segments could potentially present the antigen in a form that resembles the original tertiary MOMP structure and thereby would be more likely to induce a useful immune response. Therefore, some hydrophobic amino acids were kept in the chimeric MOMP. We are aware that the inclusion of these short hydrophobic stretches into the primary structure of our MOMP chimera does not necessarily induce a stable or immunogenic conformation. However, our results do show that the chimera indeed fulfils its task, i.e. ease of production and purification and induction of synthesis of functional antibodies against the full-length MOMP: the rabbit antibodies we raised using the chimeric MOMP recognize full length MOMP in Ct elementary bodies (Fig. 6) .
Notwithstanding, our designed chimera would be considerably more soluble than the full-length MOMP and therefore more readily expressed in transgenic plants. In fact, in the novel chimeric construct, the VS2 and VS4 loops and the linker comprised 75% of the polypeptide, the hydrophobic residues of transmembrane part of the full-length MOMP (according to the model described by Findlay et al [26] ), only being 19% of the amino acid content. Indeed, succesful expression of the MOMP chimera was obtained in all three systems (E. coli, Arabidopsis, and carrot).
In fact, stable integration of the transgene was demonstrated in Arabidopsis over at least six generations, which was proven by immunoblot analysis (Fig. 7a ) and in carrot we were able to achieve a high expression level of chimeric MOMP -up to 3% of TSP. The stability of the transgene in the offspring is important for the possibility of scaling up transgenic plant production. As was demonstrated by Lindh et al. [33, 34] , both A. thaliana and carrot are eaten raw by mice and therefore can function as model immunization vectors in immunological and challenge studies, as well as in pre-clinical trials. Animal experiments using transgenic Arabidopsis plants for oral administration are under way, as well as experiments using purified chimeric MOMP for intranasal mucosal administration. 
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Highlights
• We designed a Chlamydia trachomatis MOMP chimera containing major antigenic epitopes • The chimera was successfully produced in E. coli, carrot and Arabidopsis thaliana • Arabidopsis plants stably express the MOMP chimera over at least six generations • Purified MOMP chimera retained antigenicity when injected into rabbits • Anti-MOMP chimera antibodies was reactive against C. trachomatis elementary bodies
